NCT02757079View on ClinicalTrials.gov

Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 21, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

July 6, 2018

Conditions

Sleep DisordersNeurodevelopmental Disorder

Interventions

DRUG

NPC-15

NPC-15, Melatonin granule 1 mg, 2 mg or 4 mg, once a day, is administered orally before going to bed for 26 weeks after a screening phase of 2 weeks with placebo administration.